Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response

Sumatriptan is effective in the acute treatment of migraine. However, about 15% of patients with migraine do not experience headache relief after sumatriptan, and up to 40% may experience recurrence of headache within 24 hours. We studied whether pharmacokinetic or pharmacodynamic differences may explain these different clinical effects.

[1]  L. Milne.  Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. , 1992, The New England journal of medicine.

[2]  M. Moskowitz.  Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. , 1992, Trends in pharmacological sciences.

[3]  Giuseppe Orefice,et al.  Flunarizine in Prophylaxis of Childhood Migraine: A Double-Blind, Placebo-Controlled, Crossover Study , 1988, Cephalalgia : an international journal of headache.

[4]  M. Ferrari,et al.  Sumatriptan in clinical practice , 1996, Neurology.

[5]  J. Olesen,et al.  Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan , 1991, The Lancet.

[6]  M. Ferrari,et al.  Clinical and experimental effects of sumatriptan in humans. , 1993, Trends in pharmacological sciences.

[7]  M. Ferrari,et al.  Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks , 1992, Neurology.

[8]  G. Plosker,et al.  Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. , 1994, Drugs.

[9]  N. Cutler,et al.  Oral Sumatriptan in Pharmacokinetics in the Migrainous State , 1991 .

[10]  A. Zwinderman,et al.  Cerebral blood flow during migraine attacks without aura and effect of sumatriptan. , 1995, Archives of neurology.

[11]  M. Ferrari,et al.  5‐HT1 receptors in migraine pathophysiology and treatment , 1995, European journal of neurology.

[12]  A. K. Scott.  Sumatriptan Clinical Pharmacokinetics , 1994, Clinical pharmacokinetics.

[13]  J. Olesen,et al.  Cerebral Blood Flow Velocities are Reduced During Attacks of Unilateral Migraine Without Aura , 1995, Cephalalgia : an international journal of headache.

[14]  P. Andrew,et al.  Determination of sumatriptan succinate in plasma and urine by high-performance liquid chromatography with electrochemical detection. , 1993, Journal of Pharmacy and Science.

[15]  Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. , 1988, Cephalalgia : an international journal of headache.

[16]  M. Ferrari,et al.  Sumatriptan ‐ Nonresponders: A Survey in 366 Migraine Patients , 1996, Headache.

[17]  J. Rothrock,et al.  Treatment of acute migraine with subcutaneous sumatriptan. , 1991, JAMA.

[18]  W. Feniuk,et al.  Mode of action of the anti-migraine drug sumatriptan. , 1991, Trends in pharmacological sciences.

[19]  M. Ferrari,et al.  Risk Factors for Headache Recurrence After Sumatriptan: A Study in 366 Migraine Patients , 1996, Cephalalgia : an international journal of headache.

[20]  O. Keene,et al.  The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. , 1991, European neurology.

[21]  V. Pfaffenrath.  [Treatment of migraine attacks with sumatriptan]. , 1993, Fortschritte der Medizin.